Cleveland Clinic's Neurological Institute is a multidisciplinary institute that combines all physicians and other healthcare providers in neurology, neurosurgery, neuroradiology, the behavioral sciences and nursing who treat adult and pediatric patients with neurological disorders. This patient-focused approach to care. Our unique, fully integrated model of care, allows us to measure quality and outcomes on a continual basis, and enhances our ability to conduct clinical research.
and Clinical Nurse Specialist Stephanie Musto and I discuss an approach to pharmacologic management of adults with attention deficit hyperactivity disorder that is patterned after an innovative model of healthcare delivery, Twenty-six patients with disease duration of at least five years participated in these studies, results of which have been published. 1,2 All patients were treatment refractory, with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥ 28. OCD was judged to cause marked functional impairment in all participants. In no case had sustained efforts at exposure response prevention therapy plus pharmacotherapy reduced symptoms to a tolerable level on a long-term basis.
Patients underwent implantation of bilateral DBS leads that allowed stimulation along the dorsal-ventral extent of the anterior capsule, extending into the ventral striatum. The stimulating leads had four cylindrical electrode contacts, which could be independently programmed. As DBS lead implantation continued during the study, the implantation site was refined to become progressively more posterior, resulting in the current target just below the junction of the anterior capsule and anterior commissure.
The final stage of surgery was implantation of programmable implantable neurostimulators in the pectoral or abdominal region, usually on the same day as surgery.
Three to four weeks after surgery, psychiatrists programmed the DBS in the outpatient setting. Patients were monitored at least monthly. Seventeen of the 26 patients had at least 24 months of follow-up and 12 reached 36 months. The majority of patients continue in follow-up with active stimulation.
Encouraging Outcomes
During the follow-up period, approximately two-thirds of patients experienced clinically significant symptom reduction and functional improvement. DBS was well tolerated overall, and adverse effects were largely transient. Results generally improved in patients implanted later in the study, when more posterior sites were investigated.
Mean YBOCS scores decreased after DBS, from average OCD severity at presurgical baseline of 34.0 ± 0.5 to 20.9 ± 2.4 at 36 months (P = 0.002). This degree of improvement was apparent by the third month of active stimulation. Categorically, the percentage of patients meeting the full response criterion (≥ 35 percent YBOCS decrease) increased from 28 percent at one month to 61 percent at last follow-up.
Global Assessment of Functioning scores improved significantly, from the presurgical baseline mean of 34.8 ± 1.1 to 59.0 ± 3.3 at last follow-up (P = 0.006).
Comorbid depressive symptoms also improved; improvement in affect and mood appeared to precede that in OCD itself. Similarly, improvement occurred in self-care; ADHD is a neuropsychiatric disorder associated with significant psychological, interpersonal and vocational disability and distress. Half of children diagnosed with ADHD will continue to have disabling symptoms and behaviors in adulthood. Common comorbidities, such as depressive, anxiety and substance use disorders, contribute to the pattern of disability.
Before joining the group, each patient undergoes a thorough psychiatric and medical (when indicated) evaluation. Some members have returned to individual treatment because one or more comorbid disorders have come to dominate the clinical picture. In our experience, sleep apnea, especially in males, has been more frequent than expected.
Pharmacologic intervention yields significant rewards for patients with ADHD. Conventional medications include amphetamine and methylphenidate compounds such as Adderall XR ® , Vyvanse ™ , Ritalin LA ® and Concerta ® . Finding the optimal dose of the correct compound in any one patient -particularly in those with medical and/or psychiatric comorbidities -can be tricky, and much group time is devoted to this process. Patients value hearing about the treatment experiences of others and the many different types of treatment. An unexpected finding is that a core group of patients has returned regularly to the monthly group meeting for more than just medication monitoring. They seem to value the supportive aspect of being in a therapeutic group.
The DIGMA format permits us to see more patients per unit of time, and allows each patient more therapeutic exposure than received in a standard, 20-minute individual visit. Monthly sessions are designed to accommodate eight to 12 patients; generally, eight to 10 show up. Vital signs as well as patient-rated depression and anxiety scales are obtained before each 90-minute session, which is led by the psychiatrist and psychiatric nurse practitioner. While the focus is on medication management, other common themes include time management, appropriate interaction with work personnel and self-esteem.
DIGMA represents an opportunity to provide care more efficiently and cost-effectively. Although our data collection is not yet adequate to verify the benefits of group therapy for adult ADHD patients, anecdotal evidence indicates high patient satisfaction. These individuals tend to judge themselves harshly, and may be disheartened that they have not achieved what they hoped for or expected. In group, they find that they are not alone, and that difficulties reaching their goals can be overcome with effective treatment. 
Improving Patient Outcomes
Consolidation presents a unique opportunity to leverage the strengths of the numerous behavioral health programs distributed among Cleveland Clinic's main campus, 10 community hospitals and 17 family health centers throughout northeast Ohio.
The pattern for this reorganization is Cleveland Clinic's institute model, a disease-specific, patient-focused, center-based approach that has encouraged collaboration among physicians and leaders systemwide. Applying this model to behavioral health, we expect to enhance our competitiveness and, most importantly, to reinforce our team's ability to deliver comprehensive therapeutic services that return patients to full functionality.
The Center for Behavioral Health will better position us to tailor treatment to individual patients, with more effective triage to the particular site where an appropriate concentration of skills and services can best meet their needs. This centralization of knowledge and expertise aims to produce better clinical outcomes and more enlightened research.
Moreover, outcomes data based on a broad regional population will be more relevant to referring physicians considering where to send their patients for specialized care. The collection of a large volume of information in the patient's electronic medical record aligns with the goals of the Neurological Institute's Knowledge Program © , which is designed to facilitate systematic analysis of care and improve outcomes.
Currently, our facilities are home to six separate inpatient adult psychiatric units, five geriatric psychiatric units, one child psychiatric unit, two chemical dependency detoxification units and myriad outpatient treatment programs.
While our multidisciplinary staff provides excellent care, a unified network will better serve patients and their physicians. We took a first step in this direction in 2005, when we relocated main campus adult psychiatric inpatient services to Lutheran Hospital, five miles to our west. Building on the success of that endeavor, we will further integrate related behavioral health resources by the end of 2009.
In addition to further consolidating adult psychiatric resources at Lutheran, we have designated other geographically dispersed community hospitals where we will combine child and adolescent and chemical dependency services.
The Center for Behavioral Health will encompass services at Cleveland Clinic's main campus as well. Clinical and administrative leadership will direct the center, bringing the regional vision that underpins this new healthcare model.
We expect the Center for Behavioral Health to offer maximum convenience to patients and their physicians, who will have one phone number to call for help around the clock. No matter where that call comes from or who makes it, streamlining the referral process is a critical first step toward restoring the patient to a productive, fulfilling life. 
B E S T P R A C T I C E Electronic Assessment
In the Department of Psychiatry and Psychology, an array of assessment tools helps quantify significant medical and psychological characteristics, including suicide risk, depression, anxiety, pain, alcohol and substance abuse risk, and overall functional ability. At the beginning of each clinical session, patients spend five to 10 minutes entering self-assessment data directly into their electronic medical record (EMR) -a novel approach that involves them more deeply in their care while saving clinicians' time. With this data, a care provider can identify an individual's risk for depression or substance abuse, for example. The clinician can then raise relevant concerns with the patient in the most appropriate and professional manner.
The electronic assessments that patients complete include:
mbia Suicide Screen Clinicians complete the Global Assessment of Functioning scale and Clinical Global Impression following each patient encounter. Departmental staff is being trained in the use of these tools to increase inter-rater reliability.
Patient-entered data are automatically stored in the Knowledge Program database and transferred into the EMR. The data can be reviewed immediately by those with access rights, providing updates on patient status and insight into clinically relevant issues that might otherwise be overlooked. Flow sheets and graphs within the program allow physicians to track changes in response to treatment and to compare patients' progress with expected outcomes. This ongoing measurement of patient status reduces the risks of bias inherent in retrospective evaluation of patient progress.
Accessible Data
Before initiation of the Knowledge Program, those wishing to conduct research on Neurological Institute patients were required to code clinical data on paper and submit the evaluations to a staffer who would key in the data -or the originators keyed it in themselves. Later, they needed to submit paper requests for information to a programming team. The programmers would then write information extractor software to search the medical record database, with results returned to the clinicians for analysis. This process could take weeks. Now, with the development of a desktop query tool, clinicians will have direct access to the Knowledge Program database to retrieve aggregate data for a particular patient population or a specific disease state.
Once the Knowledge Program contains enough data points, it will become much easier to analyze information on individual patients and treatment protocols, and to conduct trials. Retrospective analyses will be significantly easier and less expensive to perform. The data from ongoing relationships between physicians and patients will be readily available for inclusion in large trials.
These data will also be useful to demonstrate the efficacy of treatments to payors, government agencies and the public. This application is expected to become increasingly important as government programs and private insurers move toward value-based reimbursement. A patient enters self-assessment data directly into her electronic medical record before meeting with her clinician. The process saves time and engages patients in their care.
Patient-entered data are automatically stored in the Knowledge Program © database and transferred into the electronic medical record. The data can be reviewed immediately by those with access rights, providing updates on patient status and insight into clinically relevant issues that might otherwise be overlooked.
D I A G N O S T I C S
Little is known about the prevalence and characteristics of misdiagnosis among psychiatric patients. The bulk of the available literature on this topic addresses misdiagnosis of bipolar disorder and relies on retrospective chart reviews or subjective patient reporting.
Misdiagnosis of mood disorders has been linked to higher rates of psychiatric hospitalization and medical utilization as well as greater costs. Methodical investigation of misdiagnosis is warranted as a first step in the process of evidence-based psychiatric practice. 
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Other -- Further study is necessary to better understand the factors that place patients at risk for misdiagnosis and the associated potential negative treatment implications. 
Medication Management Is Critical
Anxiety disorders often accompany depression in Parkinson's disease, though they can occur independently. Anxiety disorders in these patients often have atypical presentations and occur in the setting of medicationassociated wearing-off or on-off fluctuations. Generalized anxiety and social phobias are common as well. Patients appear to respond as well as non-Parkinson's patients to selective serotonin reuptake inhibitors and benzodiazepines.
Impulse control difficulties, frequently manifested as unrestrained gambling, hypersexuality and food cravings, presumably reflect dopamine dysregulation caused by the dopamine agonists used for Parkinson's disease. Young males in particular are at risk for developing impulse control problems, although all ages and both genders are at risk. Overzealous medication usage by younger patients, whose goals are to maintain optimal marital, parental, social and/or occupational functioning, may contribute. Patient education and family therapy are critical, as is appropriate adjustment of dopaminergic agents.
Other Cognitive and Perceptual Side Effects
Visual hallucinations are another common adverse effect of dopaminergic drugs. Patients typically retain awareness that they are hallucinating but, as the disease progresses, they may lose insight. Embarrassment may prevent patients from disclosing this and other behavioral disturbances. Other potential causes of hallucination that the clinician should consider are systemic illness and dementia.
S Y M P T O M O L O G Y
Dementia in Parkinson's disease occurs in 20 to 30 percent of patients. Parkinson's dementia is a subcortical dementia characterized by slow thinking, impaired working memory and executive dysfunction due to disruption of frontal-subcortical circuits. Anti-Parkinson's drugs, especially anticholinergics, can exacerbate cognitive impairment in these patients. Anticholinesterase inhibitors such as rivastigmine (Exelon ® ) are indicated in patients with Parkinson's dementia, but typically provide only modest benefit.
Patients with Parkinson's disease face multiple physical and psychological challenges. At Cleveland Clinic, a multidisciplinary collaboration among neurology, psychiatry and neuropsychology has been effective in comprehensively addressing patient needs. 
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By Karen Broer, PhD
Though an increasingly comprehensive body of literature supports the efficacy of holistic approaches to cancer treatment, there is scant research designed to gather meaningful empirical data regarding patient experience of severe illness in relation to spiritual well-being. Such concerns as the role of spiritually oriented coping during post-diagnostic psychological adjustment and relationships between the integration of spirituality and a range of health status outcomes have been only nominally investigated. In the interest of remedying this gap in the research literature, an ongoing study is successfully adapting findings regarding the potentially positive impact of regularly practiced forms of meditation to a spiritually focused protocol with newly diagnosed leukemia patients.
Cleveland Clinic is participating in the multisite study that originated at the Hillman Cancer Center of the University of Pittsburgh Medical Center (UPMC). An earlier edition of Insights provided an overview of the study, 1 designed to assess the comparative impact of two meditation protocols -spiritually focused (SpM) and secularly focused (SM) -and a usual care/control condition (UCC) on treatment experience and long-term health outcomes for newly diagnosed acute leukemia patients. Data gathering occurs pre-intervention, post-intervention and at subsequent intervals of two, four and six months. Since its inception at UPMC in 2006, the study has been funded by the Metanexus Institute on Religion and Science, with support from the John Templeton Foundation.
Broadly, the study is designed to enhance participant coping strategies and improve quality of life throughout both hospitalization and outpatient treatment. Participants in the SpM and SM conditions take part in five manualized therapy sessions utilizing a psychoeducational format. These sessions address emotional aspects of receiving the cancer diagnosis, emphasizing emotional well-being and a meaningful life in the face of severe illness.
Administered on a one-to-one basis, each session includes therapeutic techniques of established efficacy for cancer patients, 2 followed by brief (15-to 20-minute) meditation or relaxation exercises. First and final sessions focus primarily on issues related to therapy initiation and termination, with sessions two through four covering themes highly relevant to coping with cancer: loss of control, management of treatment side effects, and separation from friends and family. The SpM meditation format integrates overt spiritual content, while the SM format includes meditations representative of standard relaxation protocols (referred to as "relaxation exercises" to avoid any prompting of spiritually oriented associations) with physiological focal points.
practiced forms of meditation to a spiritually focused protocol with newly diagnosed leukemia patients.
C O P I N G
In light of the relative absence of successful empirical research in this area, the SpM intervention was developed carefully around the specific conceptualization of spirituality as one's experience of or relationship with the sacred (defined as the source of ultimate meaning in a person's life). This intervention can be individually tailored to incorporate language and imagery specific to each participant's unique conceptualization of the sacred. Meditations provide opportunities for patients to develop and practice an experience of connection with the sacred, deriving predicted benefits such as increased comfort, support, meaning, strength and relationship. Intervention components are consistent with practices reported in the research literature. 3, 4 With more than 70 participants thus far, recruitment continues at UPMC and Cleveland Clinic through nary, but investigators hypothesize that the SpM intervention will have a more positive influence on health status outcomes than the SM or UCC conditions. Daily meditation practice rates of the SpM and SM groups will be evaluated as predictors of physical, psychological and recordings is also being conducted to identify thematic content derived from the experience of SpM participants.
It is the hope of investigators that this rigorous multimethod study will reveal findings of significant benefit to patients and families experiencing the difficult adjustment to the reality of a cancer diagnosis.
Investigators for this study are Karen Broer, PhD, and Mikkael Sekeres, MD, MS (Cleveland Clinic); Brenda Cole, PhD, and Michael Boyiadzis, MD, MHSc 
